메뉴 건너뛰기




Volumn 131, Issue 2, 2012, Pages 483-490

Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer

Author keywords

Adjuvant chemotherapy; Breast cancer; Neutropenia Prognosis; Time dependent variable

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; TAMOXIFEN;

EID: 84856235922     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1799-1     Document Type: Article
Times cited : (63)

References (39)
  • 1
    • 70849122251 scopus 로고    scopus 로고
    • Triple-negative breast cancer-current status and future directions
    • 19901010 10.1093/annonc/mdp492 1:STN:280:DC%2BD1MjnsVGjug%3D%3D
    • O Gluz C Liedtke N Gottschalk L Pusztai U Nitz N Harbeck 2009 Triple-negative breast cancer-current status and future directions Ann Oncol 20 1913 1927 19901010 10.1093/annonc/mdp492 1:STN:280:DC%2BD1MjnsVGjug%3D%3D
    • (2009) Ann Oncol , vol.20 , pp. 1913-1927
    • Gluz, O.1    Liedtke, C.2    Gottschalk, N.3    Pusztai, L.4    Nitz, U.5    Harbeck, N.6
  • 2
    • 0032547564 scopus 로고    scopus 로고
    • Polychemotherapy for early breast cancer: An overview of the randomised trials
    • DOI 10.1016/S0140-6736(98)03301-7
    • Early Breast Cancer Trialists' Collaborative Group. (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials Lancet 352 930 942 10.1016/S0140-6736(98)03301-7 (Pubitemid 28427277)
    • (1998) Lancet , vol.352 , Issue.9132 , pp. 930-942
    • Clarke, M.1    Collins, R.2    Davies, C.3    Godwin, J.4    Gray, R.5    Peto, R.6
  • 3
    • 19344364880 scopus 로고    scopus 로고
    • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials
    • (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
    • (2005) Lancet , vol.365 , pp. 1687-1717
  • 4
    • 0038688702 scopus 로고    scopus 로고
    • Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: A study by the GEICAM group
    • DOI 10.1093/annonc/mdg260
    • M Martin A Villar A Sole-Calvo R Gonzalez B Massuti J Lizon C Camps A Carrato A Casado MT Candel J Albanell J Aranda B Munarriz J Campbell E Diaz-Rubio 2003 Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group Ann Oncol 14 833 842 12796019 10.1093/annonc/mdg260 1:STN:280: DC%2BD3s3mvFGnsw%3D%3D (Pubitemid 36827198)
    • (2003) Annals of Oncology , vol.14 , Issue.6 , pp. 833-842
    • Martin, M.1    Villar, A.2    Sole-Calvo, A.3    Gonzalez, R.4    Massuti, B.5    Lizon, J.6    Camps, C.7    Carrato, A.8    Casado, A.9    Candel, M.T.10    Albanell, J.11    Aranda, J.12    Munarriz, B.13    Campbell, J.14    Diaz-Rubio, E.15
  • 6
    • 34347334619 scopus 로고    scopus 로고
    • Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma
    • DOI 10.1038/sj.bjc.6603831, PII 6603831
    • T Yamanaka S Matsumoto S Teramukai R Ishiwata Y Nagai M Fukushima 2007 Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma Br J Cancer 97 37 42 17551497 10.1038/sj.bjc.6603831 1:CAS:528:DC%2BD2sXmvV2ms7g%3D (Pubitemid 47012089)
    • (2007) British Journal of Cancer , vol.97 , Issue.1 , pp. 37-42
    • Yamanaka, T.1    Matsumoto, S.2    Teramukai, S.3    Ishiwata, R.4    Nagai, Y.5    Fukushima, M.6
  • 7
    • 66949165187 scopus 로고    scopus 로고
    • Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX
    • 19217278 10.1016/j.ejca.2009.01.019 1:CAS:528:DC%2BD1MXnsV2lu70%3D
    • K Shitara K Matsuo D Takahari T Yokota Y Inaba H Yamaura Y Sato M Najima T Ura K Muro 2009 Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX Eur J Cancer 45 1757 1763 19217278 10.1016/j.ejca.2009.01.019 1:CAS:528:DC%2BD1MXnsV2lu70%3D
    • (2009) Eur J Cancer , vol.45 , pp. 1757-1763
    • Shitara, K.1    Matsuo, K.2    Takahari, D.3    Yokota, T.4    Inaba, Y.5    Yamaura, H.6    Sato, Y.7    Najima, M.8    Ura, T.9    Muro, K.10
  • 8
    • 0031031616 scopus 로고    scopus 로고
    • Haematological toxicity: A marker of adjuvant chemotherapy efficacy in stage II and III breast cancer
    • T Saarto C Blomqvist P Rissanen A Auvinen I Elomaa 1997 Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer Br J Cancer 75 301 305 9010042 10.1038/bjc.1997.49 1:CAS:528: DyaK2sXhtFGksLY%3D (Pubitemid 27019578)
    • (1997) British Journal of Cancer , vol.75 , Issue.2 , pp. 301-305
    • Saarto, T.1    Blomqvist, C.2    Rissanen, P.3    Auvinen, A.4    Elomaa, I.5
  • 9
    • 0032774739 scopus 로고    scopus 로고
    • Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF
    • DOI 10.1038/sj.bjc.6690594
    • P Poikonen T Saarto J Lundin H Joensuu C Blomqvist 1999 Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF Br J Cancer 80 1763 1766 10468293 10.1038/sj.bjc.6690594 1:CAS:528:DyaK1MXlvFGntLw%3D (Pubitemid 29389629)
    • (1999) British Journal of Cancer , vol.80 , Issue.11 , pp. 1763-1766
    • Poikonen, P.1    Saarto, T.2    Lundin, J.3    Joensuu, H.4    Blomqvist, C.5
  • 10
    • 0348013443 scopus 로고    scopus 로고
    • Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer
    • DOI 10.1038/sj.bjc.6601366
    • DA Cameron C Massie G Kerr RC Leonard 2003 Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer Br J Cancer 89 1837 1842 14612889 10.1038/sj.bjc.6601366 1:CAS:528:DC%2BD3sXovVers7o%3D (Pubitemid 37533256)
    • (2003) British Journal of Cancer , vol.89 , Issue.10 , pp. 1837-1842
    • Cameron, D.A.1    Massie, C.2    Kerr, G.3    Leonard, R.C.F.4
  • 11
    • 77951242562 scopus 로고    scopus 로고
    • Prognostic significance of neutropenia on day one of anthracycline-based neoadjuvant chemotherapy in operable breast cancer
    • Ishitobi M, Komoike Y, Motomura K, Koyama H, and Inaji H Prognostic significance of neutropenia on day one of anthracycline-based neoadjuvant chemotherapy in operable breast cancer. Oncology 78:213-219
    • Oncology , vol.78 , pp. 213-219
    • Ishitobi, M.1    Komoike, Y.2    Motomura, K.3    Koyama, H.4    Inaji, H.5
  • 12
    • 0024469561 scopus 로고
    • Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas
    • V Le Doussal M Tubiana-Hulin S Friedman K Hacene F Spyratos M Brunet 1989 Prognostic value of histologic grade nuclear components of Scarff-Bloom- Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas Cancer 64 1914 1921 2551477 10.1002/1097-0142(19891101)64:9<1914::AID-CNCR2820640926>3.0.CO;2-G 1:STN:280:DyaK3c%2Fgt1Oqtg%3D%3D (Pubitemid 19267813)
    • (1989) Cancer , vol.64 , Issue.9 , pp. 1914-1921
    • Le Doussal, V.1    Tubiana-Hulin, M.2    Friedman, S.3    Hacene, K.4    Spyratos, F.5    Brunet, M.6
  • 15
    • 53949091207 scopus 로고    scopus 로고
    • Neutropenia occurrence and predictors of reduced chemotherapy delivery: Results from the INC-EU prospective observational European neutropenia study
    • 18351398 10.1007/s00520-008-0430-4
    • R Pettengell M Schwenkglenks R Leonard A Bosly R Paridaens M Constenla TD Szucs C Jackisch 2008 Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study Support Care Cancer 16 1299 1309 18351398 10.1007/s00520-008-0430-4
    • (2008) Support Care Cancer , vol.16 , pp. 1299-1309
    • Pettengell, R.1    Schwenkglenks, M.2    Leonard, R.3    Bosly, A.4    Paridaens, R.5    Constenla, M.6    Szucs, T.D.7    Jackisch, C.8
  • 16
    • 0347985317 scopus 로고    scopus 로고
    • Chemotherapy-Induced Neutropenia: Risks, Consequences, and New Directions for Its Management
    • DOI 10.1002/cncr.11882
    • J Crawford DC Dale GH Lyman 2004 Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management Cancer 100 228 237 14716755 10.1002/cncr.11882 (Pubitemid 38063629)
    • (2004) Cancer , vol.100 , Issue.2 , pp. 228-237
    • Crawford, J.1    Dale, D.C.2    Lyman, G.H.3
  • 17
    • 0032788580 scopus 로고    scopus 로고
    • The leucocyte nadir, a predictor of chemotherapy efficacy?
    • DOI 10.1038/sj.bjc.6690583
    • S Kvinnsland 1999 The leucocyte nadir, a predictor of chemotherapy efficacy? Br J Cancer 80 1681 10468282 10.1038/sj.bjc.6690583 1:STN:280:DyaK1Mzps1emug%3D%3D (Pubitemid 29389618)
    • (1999) British Journal of Cancer , vol.80 , Issue.11 , pp. 1681
    • Kvinnsland, S.1
  • 18
    • 0035875895 scopus 로고    scopus 로고
    • Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma
    • DOI 10.1002/1097-0142(20010615)91:12<2246::AID-CNCR1255>3.0.CO;2-4
    • C Mayers T Panzarella IF Tannock 2001 Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma Cancer 91 2246 2257 11413512 10.1002/1097-0142(20010615)91:12<2246::AID-CNCR1255>3.0.CO;2-4 1:STN:280:DC%2BD3MzkvFGksw%3D%3D (Pubitemid 32552809)
    • (2001) Cancer , vol.91 , Issue.12 , pp. 2246-2257
    • Mayers, C.1    Panzarella, T.2    Tannock, I.F.3
  • 19
    • 33749054885 scopus 로고    scopus 로고
    • Moderate Neutropenia with S-1 Plus Low-dose Cisplatin May Predict a More Favourable Prognosis in Advanced Gastric Cancer
    • DOI 10.1016/j.clon.2006.07.007, PII S0936655506002585
    • B Nakata A Tsuji Y Mitachi S Yamamitsu K Hirata T Takeuchi T Shirasaka K Hirakawa 2006 Moderate neutropenia with S-1 plus low-dose cisplatin may predict a more favourable prognosis in advanced gastric cancer Clin Oncol (R Coll Radiol) 18 678 683 10.1016/j.clon.2006.07.007 1:STN:280:DC%2BD28nmsFaqug%3D%3D (Pubitemid 44464046)
    • (2006) Clinical Oncology , vol.18 , Issue.9 , pp. 678-683
    • Nakata, B.1    Tsuji, A.2    Mitachi, Y.3    Yamamitsu, S.4    Hirata, K.5    Takeuchi, T.6    Shirasaka, T.7    Hirakawa, K.8
  • 20
    • 0027282915 scopus 로고
    • Premenopausal patients with node-positive resectable breast cancer: Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 x 6 cycles vs FEC 50 x 3 cycles vs FEC 75 x 3 cycles
    • P Fumoleau Y Devaux ML Vo Van P Kerbrat P Fargeot S Schraub J Mihura M Namer M Mercier 1993 Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 × 6 cycles vs FEC 50 × 3 cycles vs FEC 75 × 3 cycles. The French Adjuvant Study Group Drugs 45 Suppl 2 38 45 7693420 10.2165/00003495-199300452-00007 (Pubitemid 23262207)
    • (1993) Drugs , vol.46 , Issue.SUPPL. 2 , pp. 38-45
    • Fumoleau, P.1    Devaux, Y.2    Vo Van, M.L.3    Kerbrat, P.4    Fargeot, P.5    Schraub, S.6    Mihura, J.7    Namer, M.8    Mercier, M.9    Van Oosterom, A.10
  • 24
    • 0029743058 scopus 로고    scopus 로고
    • Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative
    • H Gurney 1996 Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative J Clin Oncol 14 2590 2611 8823340 1:CAS:528:DyaK28XlvVGisLg%3D (Pubitemid 26300128)
    • (1996) Journal of Clinical Oncology , vol.14 , Issue.9 , pp. 2590-2611
    • Gurney, H.1
  • 25
    • 0037156937 scopus 로고    scopus 로고
    • How to calculate the dose of chemotherapy
    • 11953888 10.1038/sj.bjc.6600139 1:CAS:528:DC%2BD38XksVSmtLs%3D
    • H Gurney 2002 How to calculate the dose of chemotherapy Br J Cancer 86 1297 1302 11953888 10.1038/sj.bjc.6600139 1:CAS:528:DC%2BD38XksVSmtLs%3D
    • (2002) Br J Cancer , vol.86 , pp. 1297-1302
    • Gurney, H.1
  • 26
    • 0031804616 scopus 로고    scopus 로고
    • Body-surface area as a basis for dosing of anticancer agents: Science, myth, or habit?
    • MJ Ratain 1998 Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 16 2297 2298 9667242 1:STN:280:DyaK1czivFyitA%3D%3D (Pubitemid 28309019)
    • (1998) Journal of Clinical Oncology , vol.16 , Issue.7 , pp. 2297-2298
    • Ratain, M.J.1
  • 27
    • 0037156942 scopus 로고    scopus 로고
    • Getting the right dose in cancer chemotherapy-time to stop using surface area?
    • 11953873 10.1038/sj.bjc.6600226 1:STN:280:DC%2BD383hs1Kmtw%3D%3D
    • DR Newell 2002 Getting the right dose in cancer chemotherapy-time to stop using surface area? Br J Cancer 86 1207 1208 11953873 10.1038/sj.bjc.6600226 1:STN:280:DC%2BD383hs1Kmtw%3D%3D
    • (2002) Br J Cancer , vol.86 , pp. 1207-1208
    • Newell, D.R.1
  • 33
    • 33645735425 scopus 로고    scopus 로고
    • Developing a new framework for dose calculation
    • DOI 10.1200/JCO.2005.05.1607
    • H Gurney 2006 Developing a new framework for dose calculation J Clin Oncol 24 1489 1490 16574997 10.1200/JCO.2005.05.1607 (Pubitemid 46638768)
    • (2006) Journal of Clinical Oncology , vol.24 , Issue.10 , pp. 1489-1490
    • Gurney, H.1
  • 34
    • 0031860380 scopus 로고    scopus 로고
    • Factors affecting epirubicin pharmacokinetics and toxicity: Evidence against using body-surface area for dose calculation
    • HP Gurney S Ackland V Gebski G Farrell 1998 Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation J Clin Oncol 16 2299 2304 9667243 1:CAS:528:DyaK1cXks1GntLw%3D (Pubitemid 28309020)
    • (1998) Journal of Clinical Oncology , vol.16 , Issue.7 , pp. 2299-2304
    • Gurney, H.P.1    Ackland, S.2    Gebski, V.3    Farrell, G.4
  • 35
    • 0029958848 scopus 로고    scopus 로고
    • Lack of relationship between systemic exposure for the component drugs of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients
    • M Sandstrom A Freijs R Larsson P Nygren ML Fjallskog J Bergh MO Karlsson 1996 Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients J Clin Oncol 14 1581 1588 8622075 1:STN:280:DyaK283gvVygtA%3D%3D (Pubitemid 26134217)
    • (1996) Journal of Clinical Oncology , vol.14 , Issue.5 , pp. 1581-1588
    • Sandstrom, M.1    Freijs, A.2    Larsson, R.3    Nygren, P.4    Fjallskog, M.-L.5    Bergh, J.6    Karlsson, M.O.7
  • 36
    • 33646517096 scopus 로고    scopus 로고
    • Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients
    • 16465545 10.1007/s00280-005-0140-2 1:STN:280:DC%2BD283js1Krtg%3D%3D
    • M Sandstrom H Lindman P Nygren M Johansson J Bergh MO Karlsson 2006 Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients Cancer Chemother Pharmacol 58 143 156 16465545 10.1007/s00280-005-0140-2 1:STN:280:DC%2BD283js1Krtg%3D%3D
    • (2006) Cancer Chemother Pharmacol , vol.58 , pp. 143-156
    • Sandstrom, M.1    Lindman, H.2    Nygren, P.3    Johansson, M.4    Bergh, J.5    Karlsson, M.O.6
  • 37
    • 1542753592 scopus 로고    scopus 로고
    • Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices
    • DOI 10.1200/JCO.2003.05.002
    • GH Lyman DC Dale J Crawford 2003 Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices J Clin Oncol 21 4524 4531 14673039 10.1200/JCO.2003.05.002 (Pubitemid 46594022)
    • (2003) Journal of Clinical Oncology , vol.21 , Issue.24 , pp. 4524-4531
    • Lyman, G.H.1    Dale, D.C.2    Crawford, J.3
  • 38
    • 10344230139 scopus 로고    scopus 로고
    • Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: A nationwide study
    • DOI 10.1200/JCO.2004.03.213
    • GH Lyman DC Dale J Friedberg J Crawford RI Fisher 2004 Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study J Clin Oncol 22 4302 4311 15381684 10.1200/JCO.2004.03.213 1:CAS:528:DC%2BD2cXhtVKju7fO (Pubitemid 41185151)
    • (2004) Journal of Clinical Oncology , vol.22 , Issue.21 , pp. 4302-4311
    • Lyman, G.H.1    Dale, D.C.2    Friedberg, J.3    Crawford, J.4    Fisher, R.I.5
  • 39
    • 0242287522 scopus 로고    scopus 로고
    • Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients
    • DOI 10.1038/sj.bjc.6601279
    • RC Leonard D Miles R Thomas F Nussey 2003 Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients Br J Cancer 89 2062 2068 14647139 10.1038/sj.bjc.6601279 1:CAS:528:DC%2BD3sXpt1CitL0%3D (Pubitemid 38030904)
    • (2003) British Journal of Cancer , vol.89 , Issue.11 , pp. 2062-2068
    • Leonard, R.C.F.1    Miles, D.2    Thomas, R.3    Nussey, F.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.